Suvaxyn PRRS MLV
porcine respiratory and reproductive syndrome virus, live
Table of contents
Overview
Suvaxyn PRRS MLV is a veterinary vaccine used to protect pigs against porcine respiratory and reproductive syndrome (PRRS). This viral disease of pigs may result in lowered farrowing (birth) rates, increase in abortions, stillborn, mummified as well as weak live born piglets and deaths. There may also be disease of the airways which can lead to high death rates in suckling and weaned pigs.
Suvaxyn PRRS MLV contains a modified strain of live PRRS virus, strain 96V198, that has been weakened so that it does not cause disease.
Authorisation details
| Product details | |
|---|---|
| Name |
Suvaxyn PRRS MLV
|
| Agency product number |
EMEA/V/C/004276
|
| Active substance |
Modified live porcine respiratory and reproductive syndrome virus
|
| International non-proprietary name (INN) or common name |
porcine respiratory and reproductive syndrome virus, live
|
| Species |
Pigs
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI09AD03
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Zoetis Belgium SA
|
| Revision |
4
|
| Date of issue of marketing authorisation valid throughout the European Union |
24/08/2017
|
| Contact address |
Rue Laid Burniat 1 |
Product information
18/08/2020 Suvaxyn PRRS MLV - EMEA/V/C/004276 - A45/0005
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Immunologicals for suidae
-
Live viral vaccines
Therapeutic indication
For active immunisation of clinically healthy pigs from 1 day of age in a porcine respiratory and reproductive syndrome (PRRS) virus contaminated environment, to reduce viraemia and nasal shedding caused by infection with European strains of PRRS virus (genotype 1).
Fattening pigs: In addition, vaccination of seronegative 1-day-old piglets was demonstrated to significantly reduce lung lesions against challenge administered at 26 weeks post vaccination. Vaccination of seronegative 2-week-old piglets was demonstrated to significantly reduce lung lesions and oral shedding against challenge administered at 28 days and at 16 weeks post-vaccination.
Gilts and sows: In addition, pre-pregnancy vaccination of clinically healthy gilts and sows, either seropositive or seronegative, was demonstrated to reduce the transplacental infection caused by PRRS virus during the third trimester of pregnancy, and to reduce the associated negative impact on reproductive performance (reduction of the occurrence of stillbirths, of piglet viraemia at birth and at weaning, of lung lesions and of viral load in lungs in piglets at weaning).